Synthesis and evaluation of 5,15-diaryltetrabenzoporphyrins as photosensitizers for photo-diagnosis and photodynamic activity of tumors.

Bioorg Chem

Department of Pharmaceutical Science and Technology, College of Biological Science and Medical Engineering, Donghua University, Shanghai 201620, China; Department of Pharmacy, Huadong Hospital, Fudan University, Shanghai 200040, China. Electronic address:

Published: October 2024

Photodynamic therapy (PDT) is a well-established treatment modality, typically conducted with single-wavelength irradiation, which may not always be optimal for varying tumor locations and sizes. To address this, photosensitizers with absorption wavelengths ranging from 550 to 760 nm are being explored. Herein, a series of 5,15-diaryltetrabenzoporphyrins (ArTBPs) were synthesized. All compounds displayed obvious absorption at 550-700 nm (especially at ∼668 nm), intense fluorescence, efficient generation of singlet oxygen and good photodynamic antitumor effects. Notably, compound I (5,15-bis[(4-carboxymethoxy)phenyl]tetrabenzoporphyrin) showed excellent cytotoxicity against Eca-109 cell line upon red light irradiation, with an IC value of 0.45 μM, and phototherapeutic index of 25.8. Flow cytometry revealed that I could induce distinct cell apoptosis. In vivo studies revealed that compound I selectively accumulated at tumor site and exhibited outstanding PDT effect with antitumor activity under single-time administration and light irradiation, and revealed more efficiency than the clinical photosensitizer Verteporfin. These findings underscore the considerable promise of I as a robust theranostic agent, offering capabilities in real-time fluorescence imaging and serving as a potent photosensitizer for personalized and precise photodynamic therapy of tumors.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bioorg.2024.107710DOI Listing

Publication Analysis

Top Keywords

photodynamic therapy
8
light irradiation
8
synthesis evaluation
4
evaluation 515-diaryltetrabenzoporphyrins
4
515-diaryltetrabenzoporphyrins photosensitizers
4
photosensitizers photo-diagnosis
4
photodynamic
4
photo-diagnosis photodynamic
4
photodynamic activity
4
activity tumors
4

Similar Publications

Background: Photodynamic therapy (PDT) is a noninvasive cancer treatment that works by using light to stimulate the production of excessive cytotoxic reactive oxygen species (ROS), which effectively eliminates tumor cells. However, the therapeutic effects of PDT are often limited by tumor hypoxia, which prevents effective tumor cell elimination. The oxygen (O) consumption during PDT can further exacerbate hypoxia, leading to post-treatment adverse events.

View Article and Find Full Text PDF

The biological applications of noncationic porphyrin-fullerene (P-F) dyads as anti-HIV agents have been limited despite the established use of several cationic P-F dyads as anti-cancer photodynamic therapy (PDT) agents. This article explores the potential of amphiphilic non-cationic porphyrin-fullerene dyads as HIV-1 inhibitors under both PDT (light-treated) and non-PDT (dark) conditions. The amphiphilic P-F dyads, PBC and PBC, demonstrated enhanced efficacy in inhibiting the entry and production of HIV-1 (subtypes B and C).

View Article and Find Full Text PDF

With the advancement of photodynamic therapy, various photosensitizers have been developed to enhance the efficacy of cancer treatment while minimizing side effects. Recently, near-infrared organic fluorophores have gained significant attention as promising photodynamic agents for cancer therapy due to their tunable photophysical properties, structural versatility, good biocompatibility, high biosafety, and synthetic flexibility. In particular, near-infrared organic photosensitizers offer several notable advantages, including deep tissue penetration, a low fluorescence background for bioimaging, and reduced damage to biological tissues compared to traditional visible-spectrum photosensitizers.

View Article and Find Full Text PDF

Advances in prostate-specific membrane antigen-targeted theranostics: from radionuclides to near-infrared fluorescence technology.

Front Immunol

January 2025

Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.

Prostate-Specific Membrane Antigen (PSMA) is a highly expressed and structurally unique target specific to prostate cancer (PCa). Diagnostic and therapeutic approaches in nuclear medicine, coupling PSMA ligands with radionuclides, have shown significant clinical success. PSMA-PET/CT effectively identifies tumors and metastatic lymph nodes for imaging purposes, while -PSMA-617 (Pluvicto) has received FDA approval for treating metastatic castration-resistant PCa (mCRPC).

View Article and Find Full Text PDF

A Multifunctional MIL-101-NH(Fe) Nanoplatform for Synergistic Melanoma Therapy.

Int J Nanomedicine

January 2025

Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.

Background: Melanoma is an aggressive form of skin cancer, and single-modality treatments often fail to prevent tumor recurrence and metastasis. Combination therapy has emerged as an effective approach to improve treatment outcomes.

Methods: In this study, we developed a multifunctional nanoplatform, MIL@DOX@ICG, utilizing MIL-101-NH(Fe) as a carrier to co-deliver the chemotherapeutic agent doxorubicin (DOX) and the photosensitizer indocyanine green (ICG).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!